Characteristics and Treatment of Anxiety Disorders in Parkinson's Disease

Dissanayaka, Nadeeka N. W., White, Elizabeth, O'Sullivan, John D., Marsh, Rodney, Silburn, Peter A., Copland, David A., Mellick, George D. and Byrne, Gerard J. (2015) Characteristics and Treatment of Anxiety Disorders in Parkinson's Disease. Movement Disorders Clinical Practice, 2 2: 155-162. doi:10.1002/mdc3.12157

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Dissanayaka, Nadeeka N. W.
White, Elizabeth
O'Sullivan, John D.
Marsh, Rodney
Silburn, Peter A.
Copland, David A.
Mellick, George D.
Byrne, Gerard J.
Title Characteristics and Treatment of Anxiety Disorders in Parkinson's Disease
Journal name Movement Disorders Clinical Practice   Check publisher's open access policy
ISSN 2330-1619
Publication date 2015-01-01
Year available 2015
Sub-type Article (original research)
DOI 10.1002/mdc3.12157
Volume 2
Issue 2
Start page 155
End page 162
Total pages 8
Place of publication Milwaukee, WI United States
Publisher International Parkinson and Movement Disorder Society
Collection year 2016
Language eng
Formatted abstract
Background: Anxiety disorders are common in Parkinson's disease (PD) and are undertreated. The current study investigates demographic and PD-specific factors associated with Diagnostic and Statistical Manual (DSM-IV) anxiety disorders and subsyndromal anxiety in PD. It also examines the use of pharmacological and nonpharmacological treatments for anxiety in PD.

Methods: Ninety nondemented PD patients completed a semistructured interview. Logistic regression models were constructed examining associations between several demographic, disease-specific, and treatment factors, as well as both current syndromal, DSM-IV anxiety disorders, and subsyndromal anxiety.

Results: Associations were found between current DSM-IV anxiety disorder, as well as female gender, younger age, more severe stages of PD, and poor activities of daily living. Subsyndromal anxiety was related to a younger onset age of PD. Relationships were also found between both anxiety groups and more complications of PD therapy, as well as higher depression scores. There were no associations between anxiety and levodopa equivalent daily dosage, motor disability, and cognition. In our sample, 57% of patients with current DSM-IV anxiety disorders or subsyndromal anxiety were not currently treated with pharmacotherapy. Of those who currently received such treatment, 83% still experienced current anxiety disorders. Results suggest that anxiety is poorly recognized and treated in PD.

Conclusions: Clinical trials investigating the efficacy of pharmacotherapy, tailored psychotherapy, and combination therapy primarily focusing on anxiety are much needed, with the aim of establishing novel targeted treatment protocols for the management of subtypes of anxiety disorders in PD.
Keyword Anxiety
Parkinson's disease
Quality of life
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Mon, 29 Jun 2015, 07:42:40 EST by Nadeeka Dissanayaka on behalf of School of Psychology